Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23699494 | 0.85 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL29169377 | 0.83 | KDM4E (0.49) | ALDH1A1KDM4EHPGDMAPTCA12 | |
| SCHEMBL30100430 | 0.80 | CSNK2A1 (0.59) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL2769498 | 0.80 | CFD (0.67) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL91954 | 0.80 | CSNK2A1 (0.59) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL30362007 | 0.78 | POLB (0.63) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL536099 | 0.78 | CA12 (0.55) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL29446743 | 0.78 | CA12 (0.71) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL901309 | 0.78 | CA12 (0.71) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL503802 | 0.78 | POLB (0.70) | ALDH1A1KDM4EHPGDLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3859804-B1 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS | CANON KK (JP) | 2024-08-07 | — | — | EP | claimed |
| US-12245446-B2 | Semiconductor device having quantum dots, display device, imaging system, and moving body | CANON KABUSHIKI KAISHA (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-3859804-B1 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS | CANON KK (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220363676-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. | 2022-11-17 | — | — | US | disclosed |
| CN-110099684-B | Compounds and methods for modulating interleukin-2-inducible T cell kinase | 科尔沃斯制药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-113285024-A | Semiconductor device having quantum dots, display device, imaging system, and moving object | 佳能株式会社 | 2021-08-20 | — | — | CN | disclosed |
| US-20210242416-A1 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS, DISPLAY DEVICE, IMAGING SYSTEM, AND MOVING BODY | CANON KABUSHIKI KAISHA (JP) | 2021-08-05 | — | — | US | disclosed |
| EP-3859804-A2 | SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS | CANON KABUSHIKI KAISHA (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3534899-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | Corvus Pharmaceuticals, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| CN-110099684-A | For adjusting the Compounds and methods for of proleulzin induced T lymphocyte kinases | 科尔沃斯制药股份有限公司 | 2019-08-06 | — | — | CN | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | ALDH1A1 3523/4885KDM4E 2011/4885HPGD 1147/4885 |
| US-20220363676-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | IL2, NFATC1, IL2RA | ALDH1A1 3523/4885KDM4E 2011/4885HPGD 1147/4885 |
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | IL2, NFATC1, IL2RA | ALDH1A1 3523/4885KDM4E 2011/4885HPGD 1147/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | ALDH1A1 3523/4885KDM4E 2011/4885HPGD 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.